Israeli co Vessl Therapeutics raises $16m
Vessl’s core technology enables the company to develop treatments for a wide range of blood-vessel-related disorders.
Israeli cell-based therapy developer Vessl Therapeutics has completed a $16 million financing round led by China s RunYoung Capital. Vessl was founded in 2000 by CEO Prof. Moshe Flugelman and was formerly called MGVS.
Vessl’s core technology enables the company to develop treatments for a wide range of blood-vessel-related disorders. Vessl combines a patient’s own endothelial cells with specific genes and other synergistic cell types to create groundbreaking therapies for patients with peripheral arterial disease, coronary artery disease, end-stage renal disease, liver cirrhosis and diabetic retinopathy - patients for whom conventional treatments have failed or are unsuitable.